Table 1.
Patient characteristics.
| Characteristic | Overall population (N = 946) | Patients who discontinued cBTKi therapy (N = 739) | Patients who received post-cBTKi therapy (N = 352) |
|---|---|---|---|
| Age, median years (range) | 72.0 (33.1–88.5)a | 72.7 (33.4–88.6)b | 71.3 (36.2–88.6)c |
|
| |||
| Sex, n (%) | |||
| Male | 710 (75.1) | 560 (75.8) | 268 (76.1) |
| Female | 236 (24.9) | 179 (24.2) | 84 (23.9) |
|
| |||
| Race, n (%) | |||
| White | 766 (81.0) | 607 (82.1) | 291 (82.7) |
| Black/African American | 46 (4.9) | 32 (4.3) | 20 (5.7) |
| Asian | 24 (2.5) | 16 (2.2) | 5 (1.4) |
| Other/unknown | 110 (11.6) | 84 (11.4) | 36 (10.2) |
|
| |||
| Geographic region, n (%) | |||
| Midwest | 256 (27.1) | 204 (27.6) | 92 (26.1) |
| Northeast | 98 (10.4) | 71 (9.6) | 34 (9.7) |
| South | 371 (39.2) | 285 (38.6) | 151 (42.9) |
| West | 196 (20.7) | 161 (21.8) | 67 (19.0) |
| Missing/unknown | 25 (2.6) | 18 (2.4) | 8 (2.3) |
|
| |||
| Practice setting, n (%) | |||
| Academic | 298 (31.5) | 239 (32.3) | 117 (33.2) |
| Community | 637 (67.3) | 493 (66.7) | 230 (65.3) |
| Missing/unknown | 11 (1.2) | 7 (0.9) | 5 (1.4) |
|
| |||
| Year of MCL diagnosis, n (%) | |||
| 2011 | 46 (4.9) | 41 (5.5) | 24 (6.8) |
| 2012 | 71 (7.5) | 58 (7.8) | 28 (8.0) |
| 2013 | 98 (10.4) | 88 (11.9) | 33 (9.4) |
| 2014 | 99 (10.5) | 84 (11.4) | 45 (12.8) |
| 2015 | 132 (14.0) | 107 (14.5) | 52 (14.8) |
| 2016 | 115 (12.2) | 89 (12.0) | 48 (13.6) |
| 2017 | 133 (14.1) | 106 (14.3) | 43 (12.2) |
| 2018 | 137 (14.5) | 103 (13.9) | 49 (13.9) |
| 2019 | 77 (8.1) | 46 (6.2) | 23 (6.5) |
| 2020 | 38 (4.0) | 17 (2.3) | 7 (2.0) |
|
| |||
| Year of cBTKi discontinuation/last observed cBTKi (for those who did not discontinue) | |||
| 2014 | 30 (3.2) | 30 (4.1) | 11 (3.1) |
| 2015 | 63 (6.7) | 62 (8.4) | 31 (8.8) |
| 2016 | 85 (9.0) | 80 (10.8) | 43 (12.2) |
| 2017 | 111 (11.7) | 98 (13.3) | 45 (12.8) |
| 2018 | 153 (16.2) | 144 (19.5) | 81 (23.0) |
| 2019 | 167 (17.7) | 155 (21.0) | 70 (19.9) |
| 2020 | 191 (20.2) | 154 (20.8) | 62 (17.6) |
| 2021 | 146 (15.4) | 16 (2.2) | 9 (2.6) |
| Time from initial diagnosis, median months (range) | 14.4 (0–116.4)d | 24.0 (0.2–114.4)e | 25.2 (1.2–114.8)f |
Abbreviations: cBTKi = covalent bruton tyrosine kinase inhibitor; MCL = mantle cell lymphoma. aage at start of cBTKi therapy, bage at cBTKi discontinuation, cage at the start of post-cBTKi therapy, dtime from initial diagnosis of MCL to start of cBTKi therapy, etime from initial diagnosis of MCL to cBTKi discontinuation, ftime from initial diagnosis of MCL to start of post-cBTKi therapy.